Hydrops fetalis

Hydrops fetalis is a serious condition characterized by the abnormal accumulation of fluid in two or more fetal body compartments, including the peritoneal cavity (ascites), pleural cavity (pleural effusion), pericardial sac (pericardial effusion), and subcutaneous tissues (skin edema). It is not a single disease but rather a clinical finding that can result from a wide range of underlying causes. Hydrops fetalis is broadly classified into two categories: immune hydrops fetalis and non-immune hydrops fetalis (NIHF). Immune hydrops, historically the most common form, is caused by maternal-fetal blood group incompatibility (most notably Rh incompatibility), leading to hemolytic disease of the fetus and newborn (ICD-10: P56.0). Non-immune hydrops fetalis (ICD-10: P56.9, P83.2) accounts for approximately 76–87% of all cases today and has a diverse etiology including chromosomal abnormalities (e.g., Turner syndrome, trisomy 21), cardiovascular malformations, infections (e.g., parvovirus B19), inborn errors of metabolism (such as lysosomal storage disorders), thoracic abnormalities, twin-to-twin transfusion syndrome, and hematologic disorders such as alpha-thalassemia major. The condition affects multiple organ systems. Severe fluid accumulation impairs organ function, particularly of the heart, lungs, and liver. Additional clinical features may include polyhydramnios (excess amniotic fluid), placentomegaly (enlarged placenta), and hepatosplenomegaly. Hydrops fetalis carries a high mortality rate, particularly when it develops early in gestation or when the underlying cause is not treatable. Prognosis depends heavily on the etiology, gestational age at diagnosis, and severity of fluid accumulation. Treatment is directed at the underlying cause when identifiable. For immune hydrops, intrauterine transfusions have significantly improved outcomes, and Rh immunoglobulin prophylaxis has dramatically reduced its incidence. For non-immune hydrops, management may include treatment of fetal arrhythmias, drainage of fluid collections (thoracentesis, paracentesis), intrauterine transfusion for fetal anemia, or delivery planning with neonatal intensive care support. In cases caused by inborn errors of metabolism, emerging therapies such as enzyme replacement therapy are being explored. Despite advances, the overall prognosis remains guarded, with survival rates for NIHF ranging from approximately 20–50% depending on the underlying etiology and access to specialized fetal medicine care.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Hydrops fetalis